AMA/AMA-M2与抗gp210/sp100双阳性对原发性胆汁性胆管炎诊断价值最高
该回顾性研究以肝活检为参考标准,分析733例抗体阳性患者,发现双抗体阳性组PBC诊断率94.22%(212/225),高于仅AMA(s)阳性组80.05%(313/391)和仅抗gp210/sp100阳性组53.85%(63/117)(p<0.05)。双阳性组胆汁淤积指标最重,145例非PBC患者随访中位39.10个月后2.07%(3/145)进展为PBC。
要点
- 双抗体阳性组PBC诊断率94.22%,显著高于单抗体阳性组。
- 双阳性组碱性磷酸酶、γ-谷氨酰转移酶、总胆汁酸和IgM水平显著更高。
- 仅抗gp210/sp100阳性组消化道出血发生率最高。
核心结论
- 肝活检仍是诊断PBC的确定性标准。
- AMA/AMA-M2与抗gp210/sp100双阳性对识别PBC的诊断价值最高。
研究设计与样本
- 回顾性研究,纳入733例接受肝活检的抗体阳性患者。
- 分为仅AMA(s)阳性组、仅抗gp210/sp100阳性组和双抗体阳性组。
- 对145例初始不符合PBC诊断标准的非PBC患者进行随访,中位随访39.10个月。
主要发现
- 733例中80.22%(588/733)诊断为PBC,19.78%(145/733)为非PBC。
- 仅AMA(s)阳性组诊断率80.05%(313/391),仅抗gp210/sp100阳性组53.85%(63/117),双抗体阳性组94.22%(212/225)(p<0.05)。
- 双抗体阳性组胆汁淤积指标最重,碱性磷酸酶、γ-谷氨酰转移酶、总胆汁酸和IgM水平显著更高。
- 仅抗gp210/sp100阳性组消化道出血发生率最高。
- 双阳性组自身免疫性肝炎重叠较仅AMA(s)阳性组更常见(p<0.05)。
关键数值与推荐
- 双抗体阳性组PBC诊断率94.22%(212/225),仅AMA(s)阳性组80.05%(313/391),仅抗gp210/sp100阳性组53.85%(63/117)。
- 非PBC患者随访中位39.10个月,PBC累积发生率7.40%。
临床怎么用
- 对AMA/AMA-M2与抗gp210/sp100双阳性患者应高度考虑PBC,但仍需肝活检确认。
- 双阳性提示更严重胆汁淤积,需关注病情评估。
- 仅抗gp210/sp100阳性者需警惕消化道出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary biliary cholangitis (PBC)-related antibodies-including anti-mitochondrial antibodies (AMA), AMA-M2, anti-gp210, and anti-sp100-can occur in non-PBC liver diseases. We evaluated single and combined antibody positivity, focusing on dual positivity, using liver biopsy as the reference standard. METHODS: This retrospective study included antibody-positive patients who underwent liver biopsy. Patients were classified into three groups: only AMA(s) positive group, only anti-gp210/sp100 positive group, and dual-antibody positive group. Clinical and biochemical characteristics were compared to evaluate diagnostic performance and disease severity. Antibody-positive patients who did not initially meet diagnostic criteria for PBC were followed to assess diagnostic conversion. RESULTS: Among 733 antibody-positive patients, 80.22% (588/733) were diagnosed with PBC, while 19.78% (145/733) were non-PBC. Diagnostic rates were 80.05% (313/391) in the only AMA(s) positive group, 53.85% (63/117) in the only anti-gp210/sp100 positive group, and 94.22% (212/225) in the dual antibody positive group (p < 0.05). Dual antibody positive patients showed the most severe cholestatic profile, with significantly higher alkaline phosphatase, gamma-glutamyl transferase, total bile acid, and immunoglobulin M levels. The only anti-gp210/sp100 positive group had the highest rate of gastrointestinal bleeding. Autoimmune hepatitis overlap was more common in the dual-positive group than the only AMA(s) positive group (p < 0.05). Among 145 non-PBC patients followed for a median of 39.10 months, 2.07% (3/145) progressed to PBC, with a cumulative incidence of 7.40%. CONCLUSIONS: Histopathology remains the definitive standard for diagnosing PBC. Dual positivity for AMA/AMA-M2 and anti-gp210/sp100 showed the highest diagnostic value in identifying PBC.
引用
- Liu HL, Liu X, Hu YF, et al. Dual Positivity for AMA/AMA-M2 and Anti-gp210/sp100 Shows Highest Diagnostic Value for Primary Biliary Cholangitis. Aliment Pharmacol Ther. 2026. PMID: 41845567. doi:10.1111/apt.70614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。